Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.75 |
| ▸ | IGF2R | P11717 | 4/20 | 0.56 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.53 |
| ▸ | UMPS | P11172 | 4/20 | 0.42 |
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19442388 | 1.00 | FBP1 (0.75) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL22906201 | 1.00 | FBP1 (0.75) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL18464493 | 1.00 | FBP1 (0.75) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL16502555 | 0.87 | FBP1 (0.57) | FBP1IGF2RAMDHD2 | |
| SCHEMBL16502638 | 0.87 | FBP1 (0.57) | FBP1IGF2RAMDHD2 | |
| SCHEMBL24454421 | 0.86 | FBP1 (0.56) | FBP1IGF2R | |
| SCHEMBL30189347 | 0.86 | FBP1 (1.00) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL20154711 | 0.86 | FBP1 (1.00) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL19321572 | 0.85 | FBP1 (0.54) | FBP1IGF2RAMDHD2DNPH1 | |
| SCHEMBL18289603 | 0.85 | FBP1 (0.54) | FBP1IGF2RAMDHD2DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-07 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9675668-B2 | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 | MODERNA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9587003-B2 | Modified polynucleotides for the production of oncology-related proteins and peptides | MODERNATX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9572896-B2 | In vivo production of proteins | MODERNATX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9572897-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX INC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9512456-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2013130161-A1 | METHODS OF RESPONDING TO A BIOTHREAT | modeRNA Therapeutics (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013106496-A1 | METHODS AND COMPOSITIONS FOR TARGETING AGENTS INTO AND ACROSS THE BLOOD-BRAIN BARRIER | modeRNA Therapeutics (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013096709-A2 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | PHAX, IGF2BP1, NSUN2 | FBP1 4334/4885IGF2R 677/4885AMDHD2 3106/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | FBP1 1562/4885IGF2R 777/4885AMDHD2 392/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | FBP1 1562/4885IGF2R 777/4885AMDHD2 392/4885 |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | IGF2BP1, PHAX, IGF2BP2 | FBP1 3836/4885IGF2R 1857/4885AMDHD2 1827/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | FBP1 2121/4885IGF2R 2460/4885AMDHD2 206/4885 |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | IGF2BP1, IGF2BP2, NSUN2 | FBP1 3966/4885IGF2R 1250/4885AMDHD2 3561/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | FBP1 3700/4885IGF2R 832/4885AMDHD2 1550/4885 |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | FBP1 3278/4885IGF2R 1528/4885AMDHD2 3898/4885 |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | TIA1, PAIP1, PHAX | FBP1 4217/4885IGF2R 2297/4885AMDHD2 2642/4885 |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | MSH2, POLRMT, POLN | FBP1 3480/4885IGF2R 1021/4885AMDHD2 3944/4885 |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | FBP1 388/4885IGF2R 387/4885AMDHD2 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.